Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Trellus Health PLC ( (GB:TRLS) ) is now available.
Trellus Health plc, a provider of digital resilience-based care solutions for chronic conditions via its Trellus Elevate platform, focuses on whole-person condition management for high-burden gastrointestinal diseases and partners with pharmaceutical companies to improve patient engagement and outcomes. Founded by Mount Sinai experts and listed on AIM under ticker TRLS, the company leverages proprietary methodologies to deliver proven cost savings and better long-term health results.
Trellus Health has issued 48,718,698 new ordinary shares following the conversion of £50,000 of principal under its second tranche of secured convertible loan notes, increasing its total shares in issue to 371,048,919. The new shares are expected to be admitted to trading on AIM around 21 April 2026, modestly diluting existing shareholders while updating the total voting rights figure used for regulatory disclosure thresholds.
Spark’s Take on TRLS Stock
According to Spark, TipRanks’ AI Analyst, TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company focused on value-based, technology-enhanced management of complex chronic conditions through its Trellus Elevate platform, which combines data analytics, resilience-based methodology, and personalised coaching. The company initially targets high-cost gastrointestinal diseases such as inflammatory bowel disease, demonstrating significant reductions in hospitalisations and emergency room visits, and also supports pharmaceutical partners from clinical trials to commercialisation.
Average Trading Volume: 12,191,596
Technical Sentiment Signal: Sell
Current Market Cap: £805.8K
See more data about TRLS stock on TipRanks’ Stock Analysis page.